Clinical Trials · NCT07347080
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
- Phase
- EARLY_Phase 1
- Recruitment status
- Recruiting
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
- Enrollment
- 9
- Start date
- Jan 2026
- Locations
- 1 site, China
- Primary endpoint
- Incidence of Treatment-Emergent Adverse Events (TEAEs)